Related references
Note: Only part of the references are listed.Activity of Cefiderocol and Comparators against Isolates from Cancer Patients
Kenneth V. I. Rolston et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus
Rebekah M. Dedrick et al.
NATURE MEDICINE (2019)
Early clinical experience of bacteriophage therapy in 3 lung transplant recipients
Saima Aslam et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2019)
In Vivo Pharmacodynamic Study of Cefiderocol, a Novel Parenteral Siderophore Cephalosporin, in Murine Thigh and Lung Infection Models
Rio Nakamura et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Stronger together? Perspectives on phage-antibiotic synergy in clinical applications of phage therapy
Anca M. Segall et al.
CURRENT OPINION IN MICROBIOLOGY (2019)
Cefiderocol for treatment of complicated urinary tract infections
Florian M. E. Wagenlehner et al.
LANCET INFECTIOUS DISEASES (2019)
Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report
N. Hoyle et al.
RESEARCH IN MICROBIOLOGY (2018)
Antibiotic multidrug resistance in the cystic fibrosis airway microbiome is associated with decreased diversity
Andrea Hahn et al.
HELIYON (2018)
Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa
Benjamin K. Chan et al.
SCIENTIFIC REPORTS (2016)
Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients
C. R. Hansen et al.
JOURNAL OF CYSTIC FIBROSIS (2010)
Phage-Antibiotic Synergy (PAS): β-Lactam and Quinolone Antibiotics Stimulate Virulent Phage Growth
Andre M. Comeau et al.
PLOS ONE (2007)
Share Paper
